High-intensity Focused Ultrasound (HiFU) Expert Views

High-intensity Focused Ultrasound (HiFU) is a non-surgical treatment for Parkinson's that creates precise lesions in the brain to address symptoms like tremor, rigidity, and slowness. Unlike Deep Brain Stimulation (DBS), HiFU does not involve surgery, avoiding risks like infection or brain damage. It also has advantages over radiation-based treatments, as its effects are immediate and can be tested during the procedure. However, HiFU is irreversible, unlike DBS, which can be adjusted or turned off. While DBS remains the gold standard, HiFU could be a promising option for patients who cannot or do not want to undergo surgery. Clinical trials are ongoing to determine its effectiveness for different Parkinson's symptoms.

Dr. Michael Okun discusses the use of High-intensity Focused Ultrasound (HiFU) for Parkinson's disease, emphasizing its role in treating tremors, dyskinesia, and on-off fluctuations. He notes that HiFU is typically used for one-sided therapy, as creating lesions in the brain can lead to irreversible changes. While HiFU has fewer side effects compared to other treatments like Deep Brain Stimulation (DBS), its accuracy is lower because it operates externally and doesn't involve direct brain mapping. Dr. Okun highlights the need for further studies to determine the best targets and patient profiles for HiFU, as current outcomes are less favorable compared to traditional surgical methods. He also mentions advancements in DBS technology, which allow for real-time brain signal sensing and improved precision.

High-intensity Focused Ultrasound (HiFU) is a surgical treatment for Parkinson's that uses sound waves instead of a scalpel to target and destroy specific brain areas responsible for symptoms like tremors. Unlike Deep Brain Stimulation (DBS), HiFU does not involve implanting a device or allow for post-surgery adjustments. The procedure is performed with millimeter-level accuracy under MRI guidance, and patients are awake and off medication during the treatment to ensure symptoms are visible. While it offers immediate results, it is irreversible, unlike DBS, which allows for adjustments after surgery.

High-intensity Focused Ultrasound (HiFU) is an exciting advancement for treating Parkinson's disease, particularly for patients with severe tremors. Dr. Fischman explains that HiFU is following the path of Deep Brain Stimulation (DBS) by targeting specific areas of the brain. Unlike DBS, HiFU uses a 'pathless' technology, meaning it avoids physical probes and focuses only on the target area, potentially reducing cognitive side effects. HiFU was approved for Parkinson's treatment in November 2018, and researchers are exploring its use for other brain targets, such as the subthalamic nucleus, which could help manage dyskinesia but requires careful application to avoid abnormal movements.

High-intensity Focused Ultrasound (HiFU) is a newer, less invasive treatment for Parkinson's tremors and other types of tremors, such as benign essential tremors. It uses high-frequency sound waves to target and destroy specific cells in the basal ganglia area of the brain with pinpoint accuracy. Unlike Deep Brain Stimulation (DBS), HiFU is an outpatient procedure and does not require general anesthesia or intubation, making it a simpler and less invasive option.

Dr. Okun explains that High-intensity Focused Ultrasound (HiFU) is a non-invasive treatment for Parkinson's that uses sound waves to target specific areas of the brain. This method avoids the need for drilling into the skull, making it less invasive than traditional surgeries. However, it is less precise than methods like deep brain stimulation, and once a lesion is made, it cannot be reversed or adjusted. HiFU has shown effectiveness in treating tremors and some Parkinson's symptoms, but it is not suitable for everyone. Additionally, it has potential for breaking the blood-brain barrier, which could allow for new drug and gene therapy delivery methods.

Dr. Rodolfo Savica from the Mayo Clinic explains that High-intensity Focused Ultrasound (HiFU) is a technique used to treat tremors in Parkinson's patients. It works by using ultrasound to create heat inside the brain, which damages specific cells responsible for tremors. This method is not the same as traditional ultrasound used for imaging, but rather it creates a heat current that targets and destroys problematic cells. Dr. Savica emphasizes that HiFU requires careful patient selection, similar to the process for deep brain stimulation.

High-intensity Focused Ultrasound (HiFU) is a modern technique that uses sound waves to target specific areas in the brain without requiring traditional open-skull surgery. This method can lesion a portion of the brain to impact circuits affected by Parkinson's, potentially providing relief for motor and movement symptoms. The expert highlights that this approach is part of neuromodulatory techniques, which have significantly advanced Parkinson's treatment.

High-intensity Focused Ultrasound (HiFU) is a promising treatment for Parkinson's disease. Experts highlight its potential beyond traditional uses, such as lesioning (creating small, targeted areas of damage in the brain). One innovative application is using HiFU to open the blood-brain barrier, a protective layer that blocks harmful substances but also limits the delivery of certain therapies. This technique could allow treatments like growth factors to reach the brain more effectively, offering new possibilities for managing Parkinson's.

Dr. Michael Okun discusses the potential of High-intensity Focused Ultrasound (HiFU) as a treatment for Parkinson's disease. He notes that while HiFU is still behind other treatments like Deep Brain Stimulation (DBS), it is emerging as an option worth considering. A study in the New England Journal of Medicine showed promising results, but lacked a comparison group to determine the ideal candidates for HiFU. Dr. Okun emphasizes the importance of individualized care and shared decision-making, as each patient's needs and disease progression are unique. He also highlights the need for further research to identify the best targets and patient profiles for HiFU.